Skip to main content
OpenTrials
Completed

NCT Number: NCT06052748

A Study to Evaluate the Efficacy and Safety of AD-223

The purpose of this study is to evaluate the efficacy and safety of AD-223

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension,Essential Cardiovascular Diseases Essential Hypertension Hypertension Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hanyang University Hospital

Seoul, South Korea

About this study

Condition or disease : hypertension

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Other inclusions applied

Exclusion criteria

  • Orthostatic hypotension with symptom
  • Other exclusions applied

Treatment and study plan

AD-223A

Drug

PO, Once daily(QD), 8weeks

AD-223B

Drug

PO, Once daily(QD), 8weeks

AD-223C

Drug

PO, Once daily(QD), 8weeks

AD-223A Placebo

Drug

PO, Once daily(QD), 8weeks

AD-223B Placebo

Drug

PO, Once daily(QD), 8weeks

AD-223C Placebo

Drug

PO, Once daily(QD), 8weeks

Primary outcomes

  1. Change rate of MSSBP

    Time frame: Baseline, Week 8

    Change from baseline in mean sitting systolic blood pressure

Sponsors and collaborators

Lead sponsor

Addpharma Inc.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 25, 2023
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.